Treatment of Diffuse Basal Cell Carcinomas and Basaloid Follicular Hamartomas in Nevoid Basal Cell Carcinoma Syndrome by Wide-Area 5-Aminolevulinic Acid Photodynamic Therapy

In vivoevaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints

“…As it turned out, there was no difference between any of the parameters evaluated for treatment response between the two sources. Consistent with previous reports pointing to the importance of PDT dose in modulating the treatment outcome, 6,36,[40][41][42] we observed regions of viable tumor [ Fig. 4(a)] even at a high incident dose of 100 J∕cm 2 possibly due to heterogeneous PpIX accumulation or light distribution.…”

Topical 5-Aminolevulinic Acid Mediated Photodynamic Therapy of Superficial Basal Cell Carcinoma Using Two Light Fractions with a Two-hour Interval: Long-term Follow-up

“…There are no other reports on long-term response of sBCC to topical ALA-PDT with which our results can be statistically compared. The total applied light fluence in our study was only 90 J/ cm^ This is much less than the fluence recommended (> 150 J/cm^) by Oseroff et al (12,26) who achieved high long-term CR rates using non-fractionated ALA-PDT. Our method has an advantage here, because application of a large light fluence in a reasonable time requires a very powerful (laser) light source, in particular for large lesions, and such a light source is not always available.…”

Photodynamic Therapy for Patients with Basal Cell Nevus Syndrome

“…It further suggests that a second benefit of equal or greater importance is prevention of clinically detectable skin malignancies in high‐risk patients, such as those with BCNS, whose nascent lesions in normal‐appearing skin are presumably destroyed while still microscopic. Oseroff and colleagues 12 treated three children with BCNS with a different topical ALA preparation, different light source, and more complex protocol requiring general anesthesia, but reported success similar to ours, with disappearance of 85% to more than 98% of visible BCCs involving 12% to 25% of the patients' body surface area (in two cases, radiation portals for prior treatment of medulloblastoma) and no new lesions after a follow‐up period of 1.8 to 6 years.…”